Prolonged activation of protein kinase Cs (PKCs) by long-term treatment of cells with phorbol ester tumor promoters down-regulates the expression of many PKCs. To investigate the molecular mechanisms involved in the down-regulation of PKCZ, we expressed the novel PKCs Z and y and various mutant forms in baby hamster kidney cells. Upon overexpression, constitutively active PKCZ, but not wild type or kinase-dead PKCZ, underwent rapid degradation to generate several lower molecular weight polypeptides. When co-expressed with active kinases, kinase-dead PKCZ with a pseudosubstrate site mutation designed to give an active conformation was down-regulated while the wild type PKCZ was not. These results suggest requirements for kinase activity and an active conformation for down-regulation of PKCZ. Treatment with the proteasome inhibitors N-AcLeu-Leu-norleucinal and lactacystin led to accumulation of PKCZ proteolytic products and potentially ubiquitinated forms. While wild type PKCZ localizes mostly to the detergent-soluble fraction of the cell, a signi®cant portion of full-length constitutively active PKCZ and of kinase-dead, active conformation PKCZ were found in the detergent-insoluble fraction. Several proteolytic fragments of constitutively active PKCZ also were found in the detergent insoluble fraction. These full-length and proteolytic fragments of PKCZ in the detergent-insoluble fraction accumulated further in the presence of proteasome inhibitors. These data suggest that active conformation PKCZ accumulates in the detergent-insoluble compartment, is degraded by proteolysis in the presence of kinase activity, and that the cleavage products undergo further degradation via ubiquitin-mediated degradation in the proteasome.
Introduction
Protein kinase C (PKC), a group of phospholipiddependent serine/threonine kinases, has been implicated in numerous intracellular signaling pathways (Newton, 1997) . At least 11 isozymes are recognized as members of the PKC family. Although all of these proteins share some structural similarities and rely on phospholipids for activation, they exhibit dierent tissue distribution, subcellular localization, and cofactor requirements (Dekker and Parker, 1994; Mellor and Parker, 1998) . The conventional PKCs (a, bI, bII, and g) require both Ca 2+ and diacylglycerol (DAG) for activation, while novel PKCs (d, e, Z, and y) are Ca 2+ -independent, and atypical PKCs (Z and l/i) are Ca 2+ -independent and DAG-or phorbol ester-resistant (Newton, 1997; Nishizuka, 1995) . These dierences argue that these isozymes have distinct functions.
Treatment of cells with phorbol esters has been used extensively to activate many PKCs. Prolonged treatment of cells with phorbol esters often causes downregulation of PKC isozymes primarily as a result of proteolysis of activated PKC isozymes rather than of diminished synthesis . However, the mechanisms involved in this proteolysis have remained unclear.
At least four potential mechanisms that are not mutually exclusive have been proposed for the downregulation of PKC. The ®rst is a conformationdependent protease sensitivity of PKC. In this scenario, activation of PKC alters the conformation and its pseudosubstrate region is disengaged from the catalytic site. The linker region between the regulatory and catalytic domains is exposed such that it has an increased susceptibility to proteases. Based on the in vitro sensitivity of PKC to various proteases, Ca 2+ -activated neutral proteases (such as calpains) were hypothesized to degrade membrane-bound PKC (Pontremoli et al., 1988) . Down-regulation of PKCa and d in membrane fractions was partially blocked by calpain inhibitor II in muscle cells (Hong et al., 1995) . Kinasedefective PKCg can be down-regulated upon treatment of COS-1 cells with phorbol esters (Freisewinkel et al., 1991) . Kinase-defective PKCa also can be downregulated in the presence of active PKCa in COS-1 cells (Pears and Parker, 1991) .
The second possibility is a vesicle-dependent, PKC activity-dependent PKC degradation. When mammalian PKCs were expressed in ®ssion yeast and activated with phorbol ester treatment, increased vesicle trac was noted (Goode et al., 1994) . It has been hypothesized that association of PKCs with the vesicles may lead to their targeting to lysosomes or some other subcellular compartment where they are degraded .
The third potential mechanism is a proteasomedependent degradation involving ubiquitination. In human ®broblasts, PKCa and e were ubiquitinated following activation with phorbol ester or with ligands for certain cell surface receptors and then degraded by proteasomes (Lee et al., 1997) . Ubiquitinated PKCa, d and e were detected in 3Y1 rat ®broblasts upon treatment with phorbol ester (Lu et al., 1998) .
Finally, proteolysis of PKC during apoptosis has suggested that PKC may be cleaved by a caspase as part of an apoptosis pathway. PKCd and y are susceptible to caspase 3-mediated proteolysis at a DEVD site present in the V3 hinge region of those isozymes (Datta et al., 1997a,b) .
While most PKCs are down-regulated in response to phorbol ester treatment, PKCZ is not down-regulated in normal human keratinocytes (Murakami et al., 1996) , human epidermal carcinoma A431 cells, skin scans carcinoma cell line SCL-1 (Greif et al., 1992) , macrophages, Mardin-Darby canine kidney cells (Chen et al., 1997) , and EL4 mouse thymoma cells (Resnick et al., 1997) . This may be due to inecient activation of PKCZ by phorbol ester, inecient down-regulation of activated PKCZ and/or up-regulation of synthesis in these cell types. In EL4 cells, synthesis of PKCZ is upregulated upon treatment with phorbol ester (Resnick et al., 1997) . We hypothesized that activated PKCZ would be degraded eciently based on the result of transient expression of constitutively active PKCZ (PKCZ CA ). This hypothesis was supported by studies demonstrating that exogenous PKCZ was degraded upon activation with phorbol ester treatment in yeast cells Greif et al., 1992) . Notably, we previously have detected degradation of PKCZ CA without phorbol ester in EL4 cells (Resnick et al., 1998) .
In this study, we investigated potential mechanisms for degradation of PKCZ in the absence of phorbol ester treatment. Using Sindbis recombinants capable of expressing PKCZ and several mutants in baby hamster kidney (BHK) cells, we found that constitutively active PKCZ (PKCZ CA ), containing the pseudosubstrate site mutation (A161E) and should be in active conformation, underwent rapid proteolysis and that this degradation required kinase activity and an active conformation. Our data suggest that PKCZ is degraded in a detergent-insoluble fraction and that the proteolyzed products are further degraded in proteasomes following ubiquitination.
Results

Rapid degradation of transiently expressed, constitutively active PKCZ in BHK cells
Using a recombinant Sindbis virus expression system, we transiently expressed PKCZ in BHK cells. Virally expressed PKCZ accumulated in a few hours at higher levels compared to endogenous PKCZ. Endogenous PKCZ can be detected in cell lysates without infection when the immunoblots are overexposed ( Figure 1a ). The result suggests that endogenous PKCZ may not in¯uence signi®cantly the interpretation of expression and degradation of exogenous wild type or mutant PKCZs expressed transiently by viral infection.
Since treatment of several cell types with phorbol esters does not down-regulate PKCZ, we examined the eect of phorbol esters on PKCs in BHK cells. At 4.5 and 12 h after treatment of cells with 100 nM phorbol 12, 13-dibutyrate (PDB), endogenous PKCa and Z were examined using immunoblotting. PKCa was mostly down-regulated at 4.5 h, and under the detectable level at 12 h, while PKCZ was not down-regulated during same time period (data not shown). When BHK cells were infected with Sindbis recombinants capable of expressing wild type PKCZ (PKCZ WT ), and treated with 100 nM phorbol 12-myristate (PMA) or PDB, PMA treatment did not alter expression or degradation of PKCZ WT within 4.5 h and minimal degradation was detected (Figure 1b) . Similar results were obtained with PDB (data not shown).
The down-regulation of other PKCs upon phorbol ester treatment suggests that activation of PKC leads its degradation. It is possible that the failure of PKCZ to be down-regulated upon phorbol ester treatment is due to the limited activation of PKCZ. To determine whether activated PKCZ can be degraded, we transiently expressed either PKCZ WT or a constitutively active version with a mutation in the pseudosubstrate site A161E (PKCZ CA ) by infecting BHK cells with Sindbis recombinants. When expressed in Sf-9 cells from a recombinant baculovirus, PKCZ CA from a cytosolic preparation showed kinase activity completely independent of lipid whereas PKCZ WT was lipiddependent. Kinase activity of PKCZ CA without lipids was comparable to that of PKCZ WT in the presence of lipid vesicles when normalized for PKC molecule Virally expressed PKCZ WT was detected as a single 78 kDa PKCZ immunoreactive band and accumulated over 4.5 h of infection (Figure 1c ). When PKCZ CA was expressed, less accumulation of 78 kDa full-length band was observed. In addition to this full-length band, several low molecular weight bands that share the PKCZ C-terminal epitope were detected as early as 1.5 h post infection (Figure 1c ). This suggests that upon expression, PKCZ CA is proteolyzed more rapidly than is PKC WT to several low molecular weight polypeptides. We observed the rapid degradation of PKCZ CA in other cell type including chicken embryo ®broblasts, murine L929 ®broblasts, and to a lesser extent in murine P815 mastocytoma cells, EL4 thymoma cells, human Jurkat lymphoma cells, and rat aortic smooth muscle cells (data not shown).
Kinase activity is required for the susceptibility of PKCZ to degradation
The above data showed that activated PKCZ was degraded; however, it is unclear whether degradation of PKCZ CA requires kinase activity or simply the conformational change accompanying activation. To distinguish between these possibilities, we generated a kinase-dead ATP site mutant (K384A) in the background of PKCZ CA , which should exhibit the active conformation (PKCZ KDA ; A161E, K384A). When PKCZ KDA was transiently expressed in BHK cells, the 78 kDa band accumulated and no signi®cant degradation products were detected (Figure 2a ).
Since the above experiment indicated that kinase activity is required for degradation, we also examined whether expression of the catalytic domain of PKCZ (PKCZ cat ) alone is sucient for PKCZ degradation. When PKCZ cat was expressed in BHK cells, we observed the accumulation of degraded products in addition to the full-length (40 kDa) PKCZ cat band (Figure 2b ). However, both the disappearance of the full-length band and the accumulation of lower molecular weight polypeptides were slower than the apparent degradation of the PKCZ CA . A similar 33 kDa band of PKCZ smaller than the catalytic domain was generated upon degradation of both PKCZ CA and PKCZ cat (Figure 2b ).
The active conformation is required for degradation of PKCZ
Although these experiments suggested that kinase activity was required for PKCZ degradation and that the active conformation alone was not sucient, they did not reveal whether the active conformation was required for degradation. To address this possibility, we examined the degradation of PKCZ WT or PKCZ KDA with co-expression of PKCZ CA as a provider of kinase activity. In the absence of ligand, neither PKCZ KDA nor PKCZ WT are active, but the PKCZ KDA should exhibit the active conformation whereas PKCZ WT should not. As described earlier, both PKCZ WT and PKCZ KDA expressed in BHK cells exhibit the accumulation of a 78 kDa full-length band with minimal breakdown products. When PKCZ WT was co-expressed with PKCZ CA , there was accumulation of this 78 kDa band comparable to that of PKCZ WT expression alone (Figure 3a ). On the other hand, when PKCZ KDA was co-expressed with PKCZ CA , accumulation of the Figure 3 Conformation-dependent degradation of PKCZ. PKCZ WT and PKCZ KDA were co-expressed in the BHK cells with PKCZ CA or PKCZ cat as a kinase activity provider at an MOI of 10 p.f.u. of each virus per cell. At 1.5, 4, and 7 h post infection, degradation of PKCZ WT (a) or PKCZ KDA alone (b) was compared with degradation of each when co-expressed with PKCZ CA . At 1.5, 3, and 4.5 h post infection, PKCZ KDA co-expressed with PKCZ cat was compared with PKCZ KDA expressed alone (c) or with PKCZ WT co-expressed with PKCZ cat (d). PKCZ speci®c polypeptides were detected as described in Figure 1 78 kDa band was considerably less than that with PKCZ KDA alone ( Figure 3b ).
Since full-length of PKCZ CA and PKCZ KDA are the same size, the degradation of the two could not be distinguished. Co-infection experiments therefore were performed using the smaller molecular weight PKCZ cat as an active kinase with PKCZ KDA as a substrate for degradation. Figure 3c shows reduced full-length PKCZ KDA accumulation when co-expressed with PKCZ cat . Unlike PKCZ KDA , PKCZ WT continues to accumulate in the presence of PKCZ cat (Figure 3d ). Since co-expression of PKCZ cat did not aect signi®cantly the expression of PKCZ WT , it is unlikely that low level accumulation of PKCZ KDA is due to low level expression by co-expression with PKCZ cat .
To con®rm degradation of PKCZ KDA upon the introduction of kinase activity, we used a staggered infection scheme with a Sindbis replicon. With this scheme, the same population of cells infected initially with a Sindbis replicon can be super-infected subsequently with other Sindbis recombinants within a few hours. We infected BHK cells with Sindbis replicon capable of expressing PKCZ KDA followed by infection with a Sindbis recombinant capable of expressing either PKCZ cat or chloramphenicol acetyltransferase (CAT) as an irrelevant protein to control for nonspeci®c eects of the expression. Degradation of PKCZ KDA was examined by immunoblot analysis. The accumulation of 78 kDa PKCZ KDA was decreased after expression of the PKCZ cat while the level of PKCZ KDA was sustained following CAT expression ( Figure 4a ). This argues that the decrease in full-length PKCZ KDA is due to PKC kinase activity not to expression of another gene.
We also examined the rate of PKCZ KDA degradation following expression of kinase activity (either PKCZ CA or PKCZ cat ) by pulse chase labeling experiments. Cells infected with a Sindbis replicon capable of expressing PKCZ KDA were labeled with 35 S-methionine. The degradation of labeled PKCZ KDA was examined upon superinfection with a Sindbis recombinant capable of expressing PKCZ CA , PKCZ cat or CAT. Immunoprecipitated PKCZ was subjected to SDS ± PAGE and autoradiography. The degradation of labeled PKCZ KDA was more rapid (t 1/2 =45 min) in the presence of either PKCZ CA or PKCZ cat when compared to that with addition of the CAT construct (t 1/2 =150 min) ( Figure 4b ).
Expression of PKCy CA facilitates degradation of PKCZ CA Goode et al. (1995) have shown that co-expression of PKCg or d with PKCe in S. pombe renders PKCe susceptible to phorbol ester-induced down-regulation. A kinase-defective form of PKC d also is susceptible to down-regulation when co-expressed with PKCg . Freisewinkel et al. (1991) showed that kinase-defective PKCg also was down-regulated upon phorbol ester treatment and this, too, might be explained by activation of endogenous PKCs. Thus several PKCs may share down-regulation machinery within the cell and activation of one PKC isozyme may contribute to down-regulation of others.
We previously reported that expression of constitutively active PKCy (PKCy CA ) generated more smaller molecular weight bands in EL4 cells than did expression of wild type PKCy (PKCy WT ) (Resnick et al., 1998) . We investigated the activation-dependent degradation of PKCy in BHK cells using Sindbis recombinants capable of expressing wild type PKCy or PKCy CA . While the majority of PKCy WT expressed in BHK cells was observed as the 72 kDa full-length protein, there was signi®cant accumulation of smaller polypeptides that are immunoreactive with the antibody raised against the PKCy C-terminal peptide. When PKCy CA was expressed transiently, more small molecular weight immunoreactive bands and very little of the full-length band (72 kDa) were observed ( Figure  5a ). This suggests that degradation of PKCy via generation of smaller molecular weight proteolytic S-methionine were removed and prewarmed complete medium was added for cold methionine chase. At the indicated times after the chase, infected cells were lysed and PKCZ was immunoprecipitated using rabbit anti-PKCZ peptide antibody. Immunoprecipitated PKCZ was subjected to SDS-PAGE and autoradiography. The relative density of the full-length labeled PKCZ KDA (0 h chase as 1) data was plotted as a function of time of chase. Error bars represent standard deviation from densitometry of three exposures. Experiments were repeated twice fragments may be kinase activity-dependent, like that of PKCZ.
We therefore examined whether co-expression of PKCy CA could induce down-regulation of PKCZ KDA . BHK cells were co-infected with Sindbis recombinants capable of expressing PKCy CA and PKCZ KDA or PKCZ WT . When co-expressed with PKCy CA , accumulation of full-length 78 kDa PKCZ KDA was decreased while that of PKCZ WT was not (Figure 5b) . However, the degradation of PKCZ KDA when co-expressed with PKCy CA was slower compared to when co-expressed with PKCZ CA (see Figure 3) .
Activation-dependent degradation of PKCZ does not require transcription
Several possible mechanisms exist for activationdependent degradation of PKC, including PKCdependent activation or induction of a protease as well as modi®cation of PKC itself such that it becomes a substrate for an existing protease. To investigate the involvement of new gene expression, we inhibited host gene expression with the transcription inhibitor, Dactinomycin. Since Sindbis virus replication is RNA-based and exclusively in the cytoplasm, synthesis of virus speci®c RNAs and proteins is not altered by treatment of BHK cells with Dactinomycin (Hahn et al., 1992) . Dactinomycin had no eect on activationdependent degradation of Sindbis-expressed PKCZ CA (data not shown). This implies that degradation of activated PKCZ does not require PKC-induced gene expression.
Proteolytic fragments of nPKCs are further degraded by ubiquitination-mediated proteasome degradation
When PKCZ CA was expressed in BHK cells, some of the PKCZ fragments we detected were larger than the catalytic domain and it is possible that these may undergo further degradation. However, our data did not reveal a precursor-product relationship among proteolytic fragments, suggesting that a dierent mechanism may account for formation of some immunoreactive bands. We examined the possibility of ubiquitination-mediated proteasome degradation of PKCZ CA and its proteolytic fragments using proteasome inhibitors. BHK cells infected with a Sindbis recombinant expressing PKCZ CA were treated with 12 mM Ac-Leu-Leu-norleucinal (LLnL), 10 mM lactacystin or vehicle (0.1% dimethyl sulfoxide (DMSO)). Greater accumulation of full-length PKCZ and proteolytic fragments occurred in the cells treated with proteasome inhibitors (Figure 6a ). In addition, several dierent molecular weight bands were newly detected in the treated cells. These bands may represent accumulation of previously undetectable proteolytic fragments. However, since some immunoreactive bands observed in the presence of proteasome inhibitors were of higher molecular weight than full-length PKCs, some of them may be modi®ed forms of PKCZ proteolytic fragments. To test this possibility, we expressed PKCZ cat in the presence of LLnL or lactacystin. With proteasome inhibitors, bands with molecular weights larger than that of PKCZ cat as well as higher molecular weight smearing were detected (Figure 6b ). These bands were approximately 9 kDa larger than PKCZ cat or the proteolytic fragments observed in the absence of LLnL, a size increase consistent with ubiquitin modi®cation. There also was a signi®cant increase in accumulation of degraded To test the possibility of PKCZ ubiquitination, PKCZ cat immunoprecipitated after treatment of cells with or without LLnL was subjected to immunoblot analysis with an anti-ubiquitin antibody. A smear of antibody-reactive bands was detected in the lysate after LLnL treatment (Figure 7) . A very high molecular weight band, possibly representing a multi-ubiquitinated form of PKCZ cat , was detected after immunoprecipitation of PKCZ. This band was PKCZ cat expression-speci®c and a corresponding band can be detected upon longer exposure of the PKCZ blot of the immunoprecipitate sample (data not shown). Interestingly, the putative ubiquitin-modi®ed PKCZ fragments that show upon treatment with proteasome inhibitors were extremely inecient for immunoprecipitation with antibody against the PKCZ C-terminal peptide ( Figure  7 ).
We also tested for possible degradation of PKCy by the proteasome. PKCy CA or the catalytic domain of PKCy (PKCy cat ) was expressed in the presence or absence of LLnL. As with PKCZ, increased accumulation of proteolytic fragments of PKCy CA and PKCy cat was observed with proteasome inhibitors. Bands of higher molecular weight than PKCy cat also were seen (data not shown). These data support the possibility of ubiquitination-mediated degradation of nPKCs by proteasomes.
The active conformation PKCZ and its proteolytic fragments accumulate in a detergent-insoluble fraction
Phorbol ester treatment promotes the dephosphorylation of PKCa and it has been proposed that dephosphorylation predisposes PKCa to proteolysis (Bornancin and Parker, 1997; Lee et al., 1996) . Carboxy terminal dephosphorylation of PKCbII also regulates the binding of PKCbII to cytoskeletal components (Edwards et al., 1999) . Collectively, these observations suggest potential involvement of a cytoskeletal component during activation dependent degradation of PKC.
We examined the subcellular distribution of PKCZ by fractionating BHK cell lysates expressing PKCZ WT , PKCZ CA , and PKCZ KDA into detergent-soluble and -insoluble fractions. Cytoskeletal components should be in the detergent-insoluble fraction. PKCZ WT was located mostly in the detergent-soluble fraction ( Figure  8a ). Treatment of these cells with phorbol esters, which fail to induce PKCZ degradation in the cells did not alter the localization (data not shown). However, full length PKCZ CA and small proteolytic fragments of PKCZ CA were located in both the detergent-soluble and -insoluble fractions (Figure 8b ). The 50 kDa proteolytic fragment was located mainly in the detergent-insoluble fraction. A signi®cant portion of PKCZ KDA also was located in the detergent-insoluble fraction (Figure 8c ), suggesting that an active conformation is required for localization in this compartment.
Treatment of cells expressing PKCZ CA with LLnL resulted in further accumulation of full-length PKCZ CA and proteolytic fragments in the detergent-insoluble fraction (Figure 8b ). PKCZ KDA also accumulated in the detergent-insoluble fraction with LLnL treatment (Figure 8c ). These results suggest accumulation of the active conformation of PKCZ in the detergent-insoluble Figure 7 Accumulation of ubiquitinated PKCZ cat in the presence of proteasome inhibitor. PKCZ cat was expressed in subcon¯uent BHK cells in the absence (7) or presence (+) of 12 mM LLnL. At 4.5 h post-infection, infected cells were collected and lysed. The cells were lysed and immunecomplexes were precipitated using normal rabbit Ig-G (Con. ppt.) or anti-PKCZ antibody (Imm. ppt.) and subjected to immunoblotting with anti-PKCZ or antiubiquitin antibody. An arrow indicates a potential multiubiquitinated form. A 50 kDa band showing in all immunoprecipitated samples is immunoglobulin heavy chain since both anti-PKCZ and anti-ubiquitin antibodies are from rabbit origin (7) or presence (+) of 12 mM LLnL were lysed. Cell lysates were fractionated into detergent-soluble (S) or -insoluble (I) fractions by centrifugation at 100 000 g for 1 h, separated by SDS ± PAGE, and subjected to immunoblotting with anti-PKCZ antibody fraction before degradation. The above data suggest that active conformation PKCZ accumulates in a detergent-insoluble compartment and kinase activity dependent degradation of PKCZ to smaller proteolytic fragments may occur in the detergent-insoluble fraction.
Discussion
We have investigated potential mechanisms for downregulation of PKCZ and PKCy by transiently expressing these isozymes and several mutant forms in BHK cells using a Sindbis virus-based expression system. This system allowed us to minimize the possible in¯uence of other PKC isozymes and transcriptional up-regulation of PKCZ caused by phorbol ester treatment.
PKCZ CA was degraded into several proteolytic products upon expression in BHK cells, while PKCZ WT was not. It is possible that overexpression of PKCZ CA may contribute observation of proteolytic fragments. PKCZ KDA , which should have the same active conformation as PKCZ CA but lack kinase activity, was not degraded, suggesting that the kinase activity of PKCZ is required for degradation of activated PKCZ. Potential roles for this kinase activity include modi®ca-tion of PKC itself, increasing vesicular trac such that PKC moves to a speci®c subcellular compartment where degradation occurs, or activation of protease activity. The kinase activity may directly autophosphorylate PKC or cause some other modi®cation including dephosphorylation of activated PKC indirectly. This modi®ed PKC may serve as a substrate for a speci®c protease or could move to the subcellular compartment where the protease is located. Lu and colleagues (Lu et al., 1998) previously showed that phorbol ester-induced down-regulation of PKC required kinase activity using PKC inhibitors and a kinase-dead PKC mutant. reported a requirement for kinase activity and modi®cation of C-terminal phosphorylation for dissociation of PKCbII from membrane. Above reports suggest that translocation of PKC from membrane may be involved in PKC down-regulation.
In addition to the kinase activity, an active conformation of PKCZ seems also to be required for degradation. With co-expression of PKCZ CA , or PKCZ cat as a source of kinase activity, PKCZ KDA , presumably in an active conformation, was downregulated while PKCZ WT with an inactive conformation was not. We do not know whether the conformational dierence itself allows PKC to be degraded or whether a speci®c modi®cation of an active conformation PKC is involved in the down-regulation. An active conformation may allow PKC to undergo more extensive phosphorylation (or dephosphorylation) in the presence of PKC activity, and only modi®ed PKC may be susceptible to degradation or speci®c subcellular targeting. Phosphorylation of C-terminal threonine 638 (Bornancin and Parker, 1996) or serine 657 (Bornancin and Parker, 1997) of PKCa or serine 660 (Edwards and Newton, 1997) or threonine 641 (Edwards et al., 1999) of PKCbII was reported to be important for the function, stability or subcellular localization of these PKCs. Recent reports suggest that multiple dephosphorylation may be required for the degradation of the PKCa (Hansra et al., 1999) .
Since the putative serine 675 phosphorylation site is within the epitope to which the antiserum was raised, potential dierential phosphorylation in the C-terminal end of PKCZ may aect antibody binding and cause misinterpretation of the expression level of PKCZ mutants. However, when we introduced S?A or S?E mutations into the putative C-terminal PKCZ phosphorylation sites, immunoreactivity of those mutants was similar to that of wild type (unpublished data).
It is possible that kinase activity for activationdependent degradation can be provided by another PKC isozyme. PKCe and a kinase defective form of PKCd were down-regulated when these were coexpressed with PKCg or PKCd in S. pombe . Our results showed that PKCZ KDA was down-regulated when co-expressed with PKCy CA (Figure 5 ). Kinase activity of PKCy might function in any of the roles proposed for kinase activity of PKCZ. However, proteolytic fragments of PKCZ KDA was not detected by immunoblotting when it was expressed with PKCy CA suggesting that degradation of PKCZ KDA was slower with PKCy CA than that with PKCZ CA . Potential dierences in subcellular localization of PKCy and PKCZ or suboptimal eciency of PKCy CA in modi®cation of PKCZ or other proteins involved in PKCZ degradation may account for this dierence.
When PKCZ CA and PKCy CA were expressed in the presence of LLnL or lactacystin at concentrations that inhibit proteasomes, we observed further accumulation of proteolytic fragments. It is unlikely that this increased accumulation is due to the increased protease activity in the presence of proteasome inhibitors since increased accumulation of proteolytic fragments did not coincide with the disappearance of the full-length PKC polypeptides (Figure 6 ). These data support the possibility that PKC degradation is a two-step process with the second step involving proteasomes. In addition to further accumulation of proteolytic fragments, we detected several new bands with molecular mass increases of approximately 9 kDa, suggestive of ubiquitin modi®cation. Furthermore, when immunoblots of BHK cells treated with LLnL or lactacystin were probed with anti-PKCZ antibody, bands larger than full-length PKCZ were detected. Those bands may represent ubiquitinated forms of full-length PKCZ, although it is possible that they are multi-ubiquitinated forms of proteolytic fragments. Similarly, when PKCZ cat or PKCy cat were expressed in BHK cells in the presence of LLnL or lactacystin, we observed new bands that were larger than the catalytic domain of PKCZ or PKCy.
Immunoblotting of immunoprecipitated PKCZ with an anti-ubiquitin antibody revealed a high molecular weight band and additional smearing that may represent multiply ubiquitinated forms immunoprecipitable with anti-PKCZ antibody, supporting the hypothesis of proteasome-mediated degradation of PKCZ. Ubiquitination also may be a potential signal for down-regulation of active PKCZ. Down-regulation of membrane receptors like the yeast G protein-coupled receptors Ste2p (Terrell et al., 1998), Ste3p (Roth and Davis, 1996) , or the tyrosine kinase receptor c-Met (Jeers et al., 1997) is controlled by ubiquitin modi®cation-mediated vesicular tracking and proteasome degradation. When PKCs were activated in the presence of proteasome inhibitors, down-regulation of PKCa, d and e was prevented and multiple ubiquitinated forms of these PKCs were detected (Datta et al., 1997a; Lee et al., 1997 ). An *180 kDa form of multiubiquitinated PKCa has been reported (Lee et al., 1997) . We also detected an immunoreactive band, which may be a multi-ubiquitinated form, at around 150 ± 200 kDa. However, we failed to detect a putative mono-ubiquitinated form with anti-ubiquitin antibody. This may result from poor immunoprecipitation of putative ubiquitinated form.
The protease(s) involved in down-regulation of PKCZ and PKCy is unknown. Previous studies showed that cPKCs were degraded by calpain in vitro (Kishimoto et al., 1989) . Down-regulation of PKCd was inhibited by treatment with a calpain inhibitor in L8 myotubes (Hong et al., 1995) . We treated BHK cells with 12 mM LLnL to block the activity of proteasomes. Full-length PKCZ CA was still proteolysed and proteolytic fragments of PKCZ CA accumulated in the presence of LLnL. Since LLnL is also a calpain inhibitor (The K i of LLnL for calpain I is 190 nM and that for calpain II is 220 nM), calpain may not be responsible for degradation of transiently expressed PKCZ CA .
Although phorbol ester treatment down-regulates most cPKCs and nPKCs, PKCZ often is not downregulated (Chen et al., 1997; Greif et al., 1992; Murakami et al., 1996; Resnick et al., 1997) . We observed rapid degradation of PKCZ CA in BHK cells, suggesting that down-regulation of PKCZ follows activation. Partially puri®ed PKCZ can bind to phorbol ester eciently and can be activated in vitro by phorbol ester (unpublished data). But phorbol ester treatment failed to translocate PKCZ WT to the detergentinsoluble fraction where active conformations (PKCZ CA and PKCZ KDA ) were found. Therefore it is possible that treatment of the cells with phorbol esters does not activate PKCZ as eciently as it does other isozymes, or that PKCZ activated by phorbol ester treatment of the cells may not translocate to the detergent-insoluble fraction eciently. A green¯uor-escent protein-PKCZ fusion construct did respond to phorbol ester with translocation to membrane suggesting interaction with phorbol ester in the membrane (unpublished data). This result is consistent with reports of other PKC isozymes examined by GFP fusion proteins .
We also observed that a signi®cant portion of active conformation full-length PKCZ (PKCZ CA and PKCZ KDA ) and proteolytic fragments of PKCZ CA are in the detergent-insoluble fraction. Treatment of the cells with proteasome inhibitors causes further accumulation of full-length PKCZ and proteolytic fragments of PKCZ in the detergent-insoluble fraction. A potential explanation for these data is that the active conformation PKCZ may translocate to the detergentinsoluble compartment and undergo degradation in that compartment. Alternatively, the active conformation and some proteolytic fragments of PKCZ (with or without further modi®cation such as phosphorylation and/or dephosphorylation) may accumulate in the detergent-insoluble compartment when further degradation by proteasomes is blocked.
In summary, our results argue that degradation of PKCZ requires not only the active PKCZ conformation but also its kinase activity. Inhibitor studies and the molecular weight of intermediate degradation products suggest a mechanism involving ubiquitin modi®cation followed by proteolysis in the proteasome. A series of PKCZ modi®cations like ubiquitination, phosphorylation and/or dephosphorylation, may control subcellular translocation of PKCZ after activation, consequently regulating down-regulation of PKCZ. Elucidation of these modi®cations may reveal additional step at which PKC activity might be controlled pharmacologically. and Gibco-BRL and used essentially according to manufacturer speci®cations. Rabbit polyclonal antibodies directed against the carboxyl termini of PKC isozymes and protein G plus-agarose were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Rabbit anti-ubiquitin antibody was purchased from StressGen Biotechnologies Corp. (Victoria, BC, Canada). Horseradish peroxidase-conjugated secondary antibodies were purchased from BioRad (Hercules, CA, USA), Santa Cruz Biotechnology, and Sigma Chemical Co. The enhanced chemiluminescence detection system (ECL) was purchased from Amersham (Arlington Heights, IL, USA).
Materials and methods
Materials
Generation of Sindbis recombinants
Double subgenomic Sindbis recombinants capable of expressing either PKCZ, PKCy, or mutants of the isozymes were described previously (Resnick et al., 1998) . Brie¯y, cDNAs encoding murine PKCZ or PKCy were subcloned in the Sindbis plasmid TE2JC1. PKCZ CA and PKCy CA were made by site-directed mutagenesis of their pseudosubstrate regions (A161E and A148E, respectively). PKCZ KDA was generated by amino acid substitution (K384A) in the ATPase site in the background of PKCZ CA , PKCZ KDA was referred to as PKCZ KD in our previous work (Resnick et al., 1998) . PKCZ cat starts with Met followed by Asn-345 to the carboxyl terminus of PKCZ (residue 648). PKCy cat starts with Met-355 as an initiation Met and continues to the end of PKCy (residue 708). A Sindbis recombinant capable of expressing CAT was described previously (Hahn et al., 1992) .
A Sindbis replicon capable of expressing PKCZ KDA was generated by excising an XbaI fragment containing the PKCZ KDA gene from pTE2JC1:PKCZ KDA and subcloning it into a SinRep5 vector. Unlike the Sindbis recombinants described above, the Sindbis replicon can be used for cells with super infection since this particle lacks the capacity to express viral structural proteins that are important for super infection inhibition (Bredenbeek et al., 1993) . Puri®ed SinRep5:PKCZ KDA and helper plasmid DH265 were tran-scribed and RNA transcripts were transfected into BHK cells by square pulse electroporation using BTX820 (BTX Inc., San Diego, CA, USA) as described previously (Resnick et al., 1998) .
Cell culture
BHK cells were obtained from American Type Culture Collection (ATCC, Rockville, MD, USA) and maintained in DMEM supplemented with 10% fetal bovine serum, 10 mg/ml penicillin, 10 mg/ml streptomycin and 2 mM glutamine. EL4 murine thymoma cells, Jurkat human lymphoma cells, P815 murine mastocytoma cells, L929 murine ®bro-blasts, primary chicken embryo ®broblasts and rat aortic smooth muscle cells were maintained as described previously (Bobak et al., 1997; Moorman et al., 1996 Moorman et al., , 1999 .
Infection of cells with dsSIN recombinants
Monolayer cells at approximately 80% con¯uency were infected with various Sindbis recombinants in PBS at a multiplicity of infection (MOI) of 20 unless otherwise noted in the ®gure legends. After 1 h, the inoculum was removed and appropriate prewarmed medium was added. For super infection, cells were infected with a Sindbis replicon capable of expressing PKCZ KDA using the same infection procedure and cultured for 2 h at 378C. The medium was removed and appropriate Sindbis recombinant was added with PBS. After 1 h, the inoculum was removed and prewarmed medium was added. At various times post infection, cells were lysed and subjected to immunoblotting.
Inhibition of transcription
Subcon¯uent (80% con¯uent) BHK cells were infected with Sindbis recombinants capable of expressing PKCZ WT . After 1 h, prewarmed medium containing 8 mM Dactinomycin was added. After 1.5 and 3 h of culture, cells were washed and lysed.
Phorbol ester treatment
Subcon¯uent BHK cells were treated with 100 nM PDB for 4.5 or 12 h and subjected to Western blot analysis. Subcon¯uent BHK cells were infected with Sindbis recombinants capable of expressing either PKCZ WT or PKCZ CA . After 1 h, prewarmed medium was added with PDB (100 nM), PMA (100 nM), or vehicle (0.01% ethanol). Cells were cultured an additional 1.5, 3, or 4.5 h and subjected to Western blot analysis.
Proteasome inhibition
Subcon¯uent BHK cells were infected with Sindbis recombinants capable of expressing PKCZ WT , PKCZ CA , or PKCy CA . After 1 h, prewarmed medium containing 12 mM LLnL, 10 mM lactacystin, or 0.1% DMSO as a vehicle was added. Cells were cultured for an additional 1.5, 3, or 4.5 h and subjected to Western blot analysis.
Pulse chase labeling with 35 S-methionine Subcon¯uent BHK cells were infected with Sindbis replicon capable of expressing PKCZ KDA at an MOI of 10 as described above. Sindbis recombinants capable of expressing PKCZ CA , PKCZ cat or CAT were used for second infection. Radiolabeling was performed simultaneously with the second infection for 1 h in PBS containing 35 S-methionine Trans label (50 mCi/ml; ICN) at 378C. Then inocula were removed and prewarmed medium with excess cold methionine was added to the labeled cells. The cells were lysed at 30 min intervals and PKCZ was immunoprecipitated using 2 mg of goat anti PKCZ antibody. Resulting immunoprecipitants were separated by electrophoresis through 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS ± PAGE),¯uorographed and exposed to X-ray ®lm. Radiolabeled bands were quantitated using a Bio-Rad densitometer using ®lms from multiple exposures.
Preparation of cellular extracts and immunoblotting
Cells (7 ± 8610 5 ) were washed with cold PBS and lysed with 200 ml of cell lysis buer (20 mM Tris-HCl, pH 7.6, 140 mM NaCl, 0.5% NP40, 0.02% NaN 3 , 2 mM sodium orthovanadate, 10 mM sodium pyrophosphate, 40 mM NaF, 1 mM dithiothreitol, 1 mM leupeptin, 10 mM phenylmethylsulphonyluoride). The crude lysates were incubated for 30 min at 08C and cell debris and nuclei were removed by centrifugation at 15 500 g for 1 min. The lysates were subjected to fractionation or immunoblotting directly. Lysates were fractionated by further centrifugation at 100 000 g for 1 h. The supernatants (detergent-soluble fraction) were transferred to new tubes and the pellets (detergent-insoluble fraction) were resuspended with cell lysis buer containing 0.5% SDS.
Immunoblotting was performed as described previously (Resnick et al., 1998) . Brie¯y, proteins were separated by SDS ± PAGE and proteins on the gels were electroblotted onto polyvinylidene di¯uroride membranes (Millipore, Bedford, MA, USA). Membranes were blocked for 1 h with blocking solution (5% skim milk and 0.25% Tween 20 in PBS) and incubated for 1 h with antibody against PKCZ or PKCy (0.4 mg/ml) in blocking solution. Immunoreactive bands were detected using horseradish peroxidase-conjugated secondary antibodies in conjunction with an ECL system.
Immunoprecipitation
Cells were infected with Sindbis recombinants capable of expressing either PKCZ cat in the presence or absence of 12 mM LLnL and were lysed as described above. Cell lysates were rocked at 48C for 1 h with 1 mg of normal rabbit immunoglobulin and 20 ml of protein G plus-agarose. Immunoprecipitates were collected by centrifugation for 5 min at 750 g. The supernatants were rocked at 48C for 2 h with rabbit anti-PKC antibody and protein G-agarose was added. After overnight rocking, immunecomplexes were collected by centrifugation for 5 min at 750 g. After washing twice with cell lysis buer, the immunoprecipitates were subjected to immunoblot analysis.
